Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets

Inclusion criteria

• Healthy male subject, aged 18 to 60 years inclusive;
• Non-smoker subject or smoker of not more than 5 cigarettes a day ;
• No history of alcohol or drug abuse
• Body Mass Index (BMI) between 18 and 27 5 kg/m2 inclusive;
• Considered as healthy after a comprehensive clinical assessment (detailed medical history and complete physical examination);
• Signing a written informed consent prior to selection;

Exclusion criteria

• Blood donation (including in the frame of a clinical study) within 2 months before administration;
• General anaesthesia within 3 months before administration;
• Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician;
• Inability to abstain from intensive muscular effort;
• No possibility of contact in case of emergency;
• Any drug intake (except paracetamol) during the last month prior to the first administration;
• History or presence of drug or alcohol abuse (alcohol consumption > 40 grams / day);
• Excessive consumption of beverages with xanthine bases (> 4 cups or glasses / day);
• Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests;
• Positive results of screening for drugs of abuse;
• Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;
• Exclusion period of a previous study;
• Administrative or legal supervision;